Published 15 days ago • loading... • Updated 15 days ago

Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study

RAHWAY, N.J.--(BUSINESS WIRE)--Sep 2, 2025-

Reposted by

Business Wire

RAHWAY, N.J.--(BUSINESS WIRE)--Sep 2, 2025-

15 days ago

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources2

Leaning Left1Leaning Right0Center0Last Updated14 days agoBias Distribution

100% Left

100% Left

Untracked bias

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

Enid News & Eagle broke the news in 15 days ago on Tuesday, September 2, 2025.

Sources are mostly out of (0)